文献速递烧伤创面修复

纳米晶银敷料与1%磺胺嘧啶银敷料治疗成人烧伤门诊随机临床试验的疗效与成本

Efficacy and costs of nanocrystalline silver dressings versus 1% silver sulfadiazine dressings to treat burns in adults in the outpatient setting: A randomized clinical trial.
PubMed 文献 · Burns · 2021-06-01

在巴西圣保罗一家转诊医院开展的随机单盲试验中,100例成人烧伤患者1:1接受纳米晶银敷料或1%磺胺嘧啶银敷料治疗。第15天完全再上皮化比例两组无显著差异(48% vs 52%,风险差-4.0个百分点,95%CI -17至9,P=0.56),纳米晶银组换药次数显著更少(均值4.1 vs 9.6,P<0.001),但平均总成本更高(I$496.37 vs I$274.73,P=0.001)。

要点

  • 第15天完全再上皮化比例两组无显著差异(48% vs 52%,P=0.56)。
  • 纳米晶银组平均换药次数显著少于磺胺嘧啶银组(4.1 vs 9.6,P<0.001)。
  • 纳米晶银组平均总成本更高(I$496.37 vs I$274.73,P=0.001),主要因敷料采购成本。

核心结论

  • 纳米晶银敷料与1%磺胺嘧啶银敷料在疗效和安全性结局上无差异证据。
  • 纳米晶银敷料与总成本增加相关,但可能因减少换药次数和人力资源负担而为机构节省费用,尤其当采购成本降低时。

研究设计与样本

  • 随机、单中心、单盲试验,在巴西圣保罗一家转诊医院开展。
  • 100例成人烧伤患者1:1随机分配至纳米晶银敷料组(n=50)或1%磺胺嘧啶银敷料组(n=50)。
  • 主要结局为随机化后第15天完全再上皮化的参与者比例。

主要发现

  • 第15天完全再上皮化比例:纳米晶银组24例(48%),磺胺嘧啶银组26例(52%),风险差-4.0个百分点(95%CI -17至9,P=0.56)。
  • 接受手术干预的患者比例两组相似(6% vs 6%),未报告局部或严重不良事件。
  • 平均换药次数:纳米晶银组4.1(SD 2.3),磺胺嘧啶银组9.6(SD 6.7),均值差-5.56(95%CI -7.57至-3.55,P<0.001)。
  • 平均总成本:纳米晶银组I$496.37(SD 445.90),磺胺嘧啶银组I$274.73(SD 182.76),均值差221.63(95%CI 89.04至354.23,P=0.001)。
  • 敷料采购成本占总成本比例:纳米晶银组79.3%,磺胺嘧啶银组15.2%。

临床怎么用

  • 在门诊成人烧伤治疗中,纳米晶银敷料可减少换药次数,但总成本更高,需结合机构采购价格和人力资源成本综合决策。

局限性

  • 单中心研究,结果外推需谨慎;需进一步开展成本-效果研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nanocrystalline silver dressings can reduce the number of changes, facilitating burn wound management. However, the evidence regarding their efficacy and cost-consequences compared to well-established treatments, such as 1% silver sulfadiazine, is still scarce. OBJECTIVE: To determine the efficacy, safety, and costs of nanocrystalline silver dressings compared to 1% silver sulfadiazine dressings to treat adult patients with burns. STUDY DESIGN AND SETTING: Randomized, single-center, single-blind trial conducted at a referral hospital in São Paulo, Brazil. METHODS: 100 adult patients were randomized 1:1 to nanocrystalline silver (n = 50) or 1% silver sulfadiazine (n = 50). The primary outcome was the proportion of participants with complete re-epithelization at day 15 after randomization. Secondary outcomes included the number of dressing changes, direct medical costs (in international dollars, I$), pain intensity, the incidence of infections, number of patients undergoing surgery, and adverse events. RESULTS: On day 15, the proportion of patients who reached the primary outcome did not differ significantly between participants treated with nanocrystalline silver dressings (24 [48%]) and those treated with 1% silver sulfadiazine dressings (26 [52%]); risk difference of -4.0 percentage points (95% confidence interval [CI], -17 to 9; P = 0.56). The number of patients undergoing surgical intervention was similar between groups (6% vs. 6%), and no local or serious adverse events were reported. The mean (standard deviation, SD) number of dressing changes in the nanocrystalline silver group was 4.1 (2.3), and the corresponding estimate in the 1% silver sulfadiazine group was 9.6 (6.7); mean difference of -5.56 (95% CI), -7.57 to -3.55, P < 0.001). Treatment with nanocrystalline silver dressing incurred significant cost reductions in medical materials, human resources, and administrative labor. However, the mean total cost with nanocrystalline silver dressing was higher compared to 1% silver sulfadiazine dressings: I$496.37 (445.90) vs. I$274.73 (182.76); mean difference = 221.63 (95% CI, 89.04 to 354.23, P = 0.001). The main driver of higher mean total costs among nanocrystalline silver-treated participants was the purchase cost of the dressings, representing 79.3% of the total cost in the nanocrystalline silver group but only 15.2% in the 1% silver sulfadiazine group. CONCLUSION: We found no evidence of a difference between nanocrystalline silver and 1% silver sulfadiazine dressings regarding efficacy and safety outcomes. Nanocrystalline silver dressings were associated with an increase in the total costs, but they could result in important savings for an institution (less changes of dressings, reducing human resources burden), especially if acquisition costs can be decreased. Additional cost-effectiveness studies are warranted. TRIAL REGISTRATION NUMBER: NCT02108535.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Moreira SS, Camargo MC, Caetano R, et al. Efficacy and costs of nanocrystalline silver dressings versus 1% silver sulfadiazine dressings to treat burns in adults in the outpatient setting: A randomized clinical trial. Burns. 2021. PMID: 34688520. doi:10.1016/j.burns.2021.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。